You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

À propos des lignes directrices

Immunotherapy

The guidelines and other documents available here provide recommendations related to immunotherapy for people affected by cancer in Ontario.

Displaying Guidelines

26 articles

Optimal Systemic Therapy for Early Female Breast Cancer

Document Status: In-Review
ID: 1-21

Sep 2014

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Document Status: Current
ID: GL 9-11

Oct 2024

Pandemic Planning Clinical Guideline for Patients with Cancer

Document Status: Current
Version: 2

Dec 2021

Position Statements for Nursing Practice in Cancer Care

Document Status: Current
Version: 2

May 2021

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Document Status: Current

Apr 2018

Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma

Document Status: Archived
ID: 8-5
Version: 2

Sep 2011

Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

Document Status: Archived
ID: 11-8
Version: 2

Oct 2015

Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

Document Status: Current
ID: 8-1
Version: 6

Mar 2024

Systemic Therapy for Advanced Gastric and Gastro-Esophageal Carcinoma

Document Status: In-Review
ID: GL 2-26
Version: 3

Aug 2022

Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Document Status: In-Review
ID: 3-15
Version: 2

Sep 2014

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Document Status: Current

Updated

Mar 2025

The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer

Document Status: Archived
ID: 1-15 Version 3
Version: 3

Sep 2011